Protirelin is a tripeptide that stimulates the release of thyrotropin and prolactin.

Proxyphylline is a derivative of theophylline which is used as a bronchodilator and for its cardiovascular properties. It selectively antagonizes A1 adenosine receptors (Ki = 82 nM for bovine brain) versus A2 adenosine receptors (Ki = 850 µM for platelets

PRT062607(P505-15) anti-SYK activity is at least 80-fold greater than its affinity For other kinases. at least 80-fold greater than its affinity For other kinases. PRT062607 potently inhibits B cell antigen receptor-mediated B cell signaling and activation (IC50 0.27 and 0.28 μM, respectively) and Fcε receptor 1-mediated basophil degranulation (IC50 0.15 μM). PRT062607 inhibits BCR-dependent secretion of the chemokines CCL3 and CCL4 by CLL cells, and leukemia cell migration toward the tissue homing chemokines CXCL12, CXCL13, and beneath stromal cells. PRT062607 furthermore inhibits Syk and extracellular signal-regulated kinase phosphorylation after BCR triggering. For the detailed information of PRT062607, the solubility of PRT062607 in water, the solubility of PRT062607 in DMSO, the solubility of PRT062607 in PBS buffer, the animal experiment (test) of PRT062607, the cell expriment (test) of PRT062607, the in vivo, in vitro and clinical trial test of PRT062607, the EC50, IC50,and Affinity of PRT062607, Please contact DC Chemicals..

Prucalopride is a selective, high affinity 5-HT receptor agonistfor 5-HT4a and 5-HT4b with Ki of 2.5 nM and 8 nM, respectively.

Prucalopride succinate is a selective, high affinity 5-HT4 receptor agonist with pKi of 8.6/8.1 for 5-HT4a/4b.

PRX-08066 is a selective 5-hydroxytryptamine receptor 2B (5-HT2BR, IC50= 3.4 nM) antagonist that causes selective vasodilation of pulmonary arteries.

PS 210 is a potent, specific activator of PDK1 that target the PIF-binding pocket of PDK1, does not alter the activity of any of the 121 kinases (S6K, PKB/Akt or GSK3)..

PS 423 is a substrate-selective inhibitor of PDK1, inhibits the phosphorylation and activation of S6K without affecting the PKB/Akt signaling pathway in HEK293 cells, the prodrug of PS210.

PS1 is a potent inhibitor of IAP family with IC50 of 36/96/33 nM for c-IAP1/c-IAP2/XIAP respectively..

PS10 (PDK inhibitor PS10) is a novel potent and highly selective pyruvate dehydrogenase kinase (PDK) inhibitor.

PS-1145 has been shown to be an IKK (IKB kinase) inhibitor.

PS-432 is an allosteric inhibitor of PKCι and PKCζ with IC50 of 16.9 and 18.5 uM, respectively.

PSB-12379 is an α,β-Methylene-ADP (AOPCP) derivative, potent, selective ecto-5′-Nucleotidase (eN, CD73) inhibitor with Ki of 9.03/2.21 nM for rat/human recombinant eN.

PSB-12431 is an α,β-Methylene-ADP (AOPCP) derivative, potent, selective ecto-5′-Nucleotidase (eN, CD73) inhibitor with Ki of 9.2 nM for rat recombinant eN.

PSB-12553 is an α,β-Methylene-ADP (AOPCP) derivative, potent, selective ecto-5′-Nucleotidase (eN, CD73) inhibitor with Ki of 9.5 nM for rat recombinant eN.

PSI-7409 is the active 5′-triphosphate metabolite of PSI-7851. PSI-7851 is a selective and highly active nucleotide analog inhibitor of HCV.

PSMA-617 is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a Ki of 0.37 nM.

PSN632408 is an optimized agonist of GPR119 receptors that shows similar potency to OEA at both recombinant mouse and human GPR119 receptors, exhibiting EC50 values of 5.6 and 7.9 uM, respectively.

PSN-GK1 is a potent, orally available Glucokinase (GK) activator with EC50 of 130 nM at 5 mM glucose (4.3-fold).

Psora-4 is a potent and selective Kv1.3 potassium channel blocker with EC50 of 3 nM.

PST-1 is a photoswitchable inhibitor of microtubule with EC50 of 0.5 uM under 390 nm irradiation in the MDA-MB-231 human breast cancer cell lines.

PST-1P is a photoswitchable inhibitor of microtubule with EC50 of 0.7 uM under 390 nm irradiation in the MDA-MB-231 human breast cancer cell lines.

PT2399(PT=2399) is a novel HIF2α Antagonist.

PTC299 (PTC-299) is a novel potent inhibitor of dihydroorotate dehydrogenase (DHODH), inhibits hypoxia-induced VEGFA protein production in HeLa cells with IC50 of 1.64 nM.

PTC725 is a potent, selective, and orally bioavailable inhibitor of HCV NS4B, inhibits HCV 1b (Con1) replicons with EC50 of 1.7 nM.

Pterosin B is a potent and specific SIK3 signaling inhibitor that suppresses SIK3 downstream cascades by up-regulating the phosphorylation levels in the SIK3 C-terminal regulatory domain.

PTGR2-IN-22 is a potent PTGR2 ligand that inhibits 15-keto-PGE2 reductase activity with IC50 of 0.55 uM in HEK293T cells.

PTP1B-IN-5b is a potent protein tyrosine phosphatase PTP1B inhibitor with IC50 of 5.25 uM.

PTUPB is a novel dual acting COX-2/sEH inhibitor with IC50 of 1.26 uM/0.9 nM,does not inhibits COX-1 (IC50>100 uM).

PU-139 is a potent, unselective HAT (Histone acetyltransferase) inhibitor that blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB protein (CBP) and p300.

PU-141 is a potent, selective CBP/p300 inhibitor that inhibits SK-N-SH cell growth with GI50 of 0.48 uM.

Pulchinenoside A is a natural triterpenoid saponin that enhances synaptic plasticity in the adult mouse hippocampus and facilitates spatial memory in adult mice.

Pulsatilla saponin D(SB365) isolated from the root of Pulsatilla koreana, has exhibited potential beneficial effects as a chemopreventive agent for critical health conditions including cancer.

Purfalcamine is a potent, specific inhibitor of Plaasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) with IC50 of 17 nM.

Puromycin Aminonucleoside (3'-Amino-3'-deoxy-N6,N6-dimethyladenosine) is the aminonucleoside portion of the antibiotic puromycin.

Puromycin is an aminoglycoside antibiotic isolated from the bacterium Streptomyces alboniger. It is a protein synthesis inhibitor.

PVZB-1194 is a bis(hetero)aryl derivative that inhibits kinesin spindle protein (KSP) ATPase witn IC50 of 0.12 uM.

PWT143 (ME-401), is an orally bioavailable inhibitor of the delta isoform of phosphatidylinositide 3-kinase (PI3K), with potential antineoplastic activity.

PWZ-029 is a potent, subtype-selective partial inverse agonist of α5 GABAA receptors with Ki of 30 nM, demonstrates memory enhancing effects in vivo.

Px-104(Px-102) is a farnesoid X receptor (FXR) agonist potentially for the treatment of non-alcoholic fatty liver disease.

PX-12(IV-2) is an irreversible inhibitor of Thioredoxin-1(Trx-1) currently in clinical development as an antitumor agent; IC50=7 uM in Hela, MTT assay, 72 h.

PX20606, also known as PX-102, is a FXR agonist.

Pyk2-IN-25a is a highly potent Pyk2 (PTK2B) inhibitor with IC50 of 0.67 nM, dispalys 2-fold weakening potency for FAK (IC50=1.26 nM).

PyP-1 is a potent, highly selective, and orally bioavailable PDE10A inhibitor with Ki of 0.23 nM.

Pyr6 is a selective inhibitor of TRPC3 with IC50 of 0.49 uM(Ca2+ influx inhibition in thapsigargin depleted native RBL-2H3 cells).

Pyrazinib (Pyrazinib (P3)) is a pyrazine phenol small molecule drug with anti-angiogenic and anti-metabolic activity in-vivo in zebrafish and in-vitro isogenic models of OAC radioresistance.

Pyridoxine hydrochloride (Pyridoxol; Vitamin B6) is a pyridine derivative. Pyridoxine (Pyridoxol; Vitamin B6) exerts antioxidant effects in cell model of Alzheimer's disease via the Nrf-2/HO-1 pathway.

Pyrimidinone 8 is a novel allosteric, non-competitive divalent metal transporter-1 (SLC11A2/DMT1) inhibitor with Ki of 20 uM.

Pyrimidyn 7 is a potent, dual-action dynamin GTPase activity inhibitor with IC50 of 1.1 uM/1.8 uM for dynamin I/dynamin II respectively, competitively inhibits both GTP and phospholipid interactions with dynamin.

Pyronaridine tetraphosphate is a Mannich base anti-malarial with demonstrated efficacy against drug resistant Plasmodium falciparum, P. vivax, P. ovale and P. malariae.

Pyrotinib maleate (SHR-1258 maleate) is a potent and selective EGFR/HER2 dual inhibitor with IC50 of 13/38 nM, respectively.

Pyrrophenone is a potent cPLA2α inhibitor with enzyme IC50 of 4.2 nM.

PYZD-4409 is a novel small molecule inhibitor of Ubiquitin-activating enzyme UBA1/E1 enzyme with an IC50 of 20 uM (cell-free enzymatic assay).

PZ09 (PKC-zeta inhibitor 9, PKC-ζ inhibitor PZ9) is a potent, isoform selective PKC-zeta (PKC-ζ) inhibitor with IC50 of 5.18 nM, displays excellent selectivity (>200-fold) over other PKC isoforms with exception of PKC-i (10-fold). PZ09 also shows high selectivity for CDK-2 (>200-fold), as well as a broader range of other kinases (<50% inhibition at 10 uM). PZ09 is a small-molecule inhibitor, the first tool to successfully interrogate aPKC signaling in cells.

PZM21 is a potent and selective μ opioid receptor agonist with an EC50 of 1.8 nM.

Q151 is a highly potent inhibitor of mycobacterium tuberculosis IMPDH2 (MtbIMPDH2) with Kiapp of 18 nM, demonstrates the minimum inhibitory concentrations (MIC) of 1 uM withour significant cytotoxicity.

QC-3611 is a selective inhibitor of JARID1A/1B, which is a target existing in various tumors (JARID1A IC50 = 13 nM ;JARID1B IC50 = 2 nM). QC-3611 is promisingly to be used as an antineoplastic drug.

QC-6352 is a potent and selective KDM4 family inhibitor with IC50 of 104, 56, 35, and 104 nM for KDM4A, KDM4B, KDM4C, and KDM4D, respectively.

QCA276 is a novel potent BET proteins inhibitor with IC50/Ki of 10/.3 nM, QCA276 is the BET ligand for PROTAC QCA570.

QCA570 is a novel, highly potent efficacious BET degrader (PROTAC).

QcrB inhibitor TB47 (TB47) is a novel antimycobacterial agent that fuctions as a putative respiratory complex III (QcrB) inhibitor with MIC of 0.016-0.5 ug/mL against a panel of 56 M. tuberculosis clinical isolates.

QD 232 is a novel quinazolinedione-based redox modulator that potently inhibits Src/FAK and STAT3 phosphorylation, decreasing pancreatic cancer cell viability and migration.

QD325 is a potent redox modulator that induces Nrf2-mediated oxidative stress and unfolded protein responses in PDAC cells (IC50=0.9 uM).

QL-IX-55 is a selective ATP-competitive inhibitor of mTORC1/2 with IC50s of 50/50/10-50 nM for Human mTORC1/Yeast mTORC1/Yeast mTORC2, respectively

QL-X-138 is a selective and potent BTK/MNK dual kinase inhibitor with IC50 of 8, 107.4, and 26 nM for BTK, MNK1, and MNK2, respectively.

QM31 (SVT016426, Apaf-1 inhibitor QM31) is a cytoprotective agent that inhibits the formation of the apoptosome (IC50=7.9 uM in vitro), the caspase activation complex composed by Apaf-1, cytochrome c, dATP and caspase-9.

QM385 is a highly potent small molecule SPR inhibitor,that inhibits the BH4 pathway, blocking T cell proliferation and autoimmunity.

QO IIR is a reversible, tight-binding inhibitor inhibitor of catechol-O-methyltransferase (COMT) with IC50 of 320 nM.

QS 11 is a GTPase activating protein of ADP-ribosylation factor 1 (ARFGAP1) inhibitor.

QStatin is a novel, potent, and selective Vibrio quorum sensing (QS) inhibitor, shows pan-QS inhibitor activity in diverse Vibrio species.

QTX125 (QTX-125) is a novel potent, selective HDAC6 inhibitor, displays excellent selectivity over other HDACs.

Quetiapine Sulfoxide is a metabolite of Quetiapine. Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and along with an antidepressant to treat major depressive disorder.

Quillaic acid(Quillaja sapogenin) is the major aglycone of the widely studied saponins of the Chilean indigenous tree Quillaja saponaria Mol; can elicit dose-dependent antinociceptive effects in two murine thermal models.

Quinalizarin is a potent, selective and cell-permeable inhibitor of CK2 with Ki of 58 nM.

Quizartinib (AC220) is a potent, selective, second-generation FLT3 inhibitor with Kd of 1.6 nM, inhibits Wt FLT3 and FLT3-ITD autophosphorylation in MV4-11cell with IC50 of 4.2 and 1.1 nM, respectively.

R121919 is a potent small-molecule CRF1 receptor antagonist with a Ki of 2 to 5 nM for the CRF1 receptor and over 1000-fold weaker activity at the CRF2 receptor, CRF-binding protein, or 70 other receptor types.

R15A inhibitor.

R191 (R-191) is a potent, small molecule IRAK1/4 kinase inhibitor (IRAK4 IC50=3 nM), exhibits good selectivity against a broad panel of kinases.

R243 is a potent, small molecule CCR8 antagonist that inhibits CCR8 signaling and chemotaxis, inhibits CCL1-induced Ca2+ flux and CCL1-driven peritoneal macrophages aggregation at 0.2 uM.

R-360163 is a small molecule inhibitor that effectively inhibits the β-catenin/Tcf4 interaction with Ki of 16 uM in FP assay.

R547 is a potent and selective CDK inhibitor with Ki and IC50 of 1-3 nM and 80 nM respectively.

R-7128(Mericitabine) is a selective nucleoside analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, with activity across all HCV genotypes.

R916562 (R562) is a potent, dual Axl/VEGF-R2 inhibitor with celluar IC50 of 136 nM for Axl.

R-999636 is a small molecule inhibitor that effectively inhibits the β-catenin/Tcf4 interaction with Ki of 8.8 uM in FP assay.

RA190, a bis-benzylidine piperidon, inhibits proteasome function by covalently binding to cysteine 88 of ubiquitin receptor RPN13.

rac Pterosin B is a potent and specific SIK3 signaling inhibitor that suppresses SIK3 downstream cascades by up-regulating the phosphorylation levels in the SIK3 C-terminal regulatory domain.

RAD51-IN-17 is a quinazolinone derivative that inhibts homologous recombinase RAD51, effectively inhibits both RAD51 foci formation in response to DNA damage, and proliferation of TNBC cell lines.

Radafaxine Hcl(BW-306U; GW-353162A) is a potent metabolite of bupropion; selective for inhibiting the reuptake of norepinephrine over dopamine; DAT (dopamine transporter) and NET(norepinephrine transporter) transporters inhibitor, and nAChR family modulat

Radalbuvir (GS-9669) is a highly optimized thumb site II nonnucleoside inhibitor of HCV NS5B polymerase with binding affinity of 1.35 nM for genotype 1b.

Radezolid (RX-1741) is a novel oxazolidinone antibiotic agent.

Rafoxanide is a salicylanilide used as an antiparasitic agent.

Raltegravir potassium salt(MK0518 potassium salt) is a potent integrase (IN) inhibitor, used to treat HIV infection.

Ramatroban (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis.

Ramelteon is a novel melatonin receptor agonist for human MT1 and MT2 receptors and chick forebrain melatonin receptors with Ki of 14 pM, 112 pM and 23.1 pM, respectively.

RapaLink-1 is a third-generation mTOR inhibitor that overcomes resistance to existing first- and second-generation inhibitors; blocks mTOR signaling of the F2108L mTOR and M2327I mTOR drug resistant mutants; RapaLink-1 is more potent mTOR inhibitor than rapamycin.

RAS activator compound 1 is a small molecule RAS activator compound that increases the rate of SOS-catalyzed nucleotide exchange in vitro with EC50 of 14 uM; targets SOS1 induced biphasic modulation of RAS-GTP and ERK phosphorylation levels, through negative feedback on SOS1 that regulates the interaction between SOS1 and GRB2.

RAS inhibitor Abd-7 is a potent RAS-binding compound (Kd=51 nM) that interacts with RAS in cells, prevents RAS-effector interactions and inhibits endogenous RAS-dependent signalling.

RasGRP3 ligand 96 is a potent, selective ligand of Ras guanine-releasing protein 3 (RasGRP3) with Ki of 1.75 nM, showed 73-fold and 45-fold selectivity relative to PKCα and PKCε for in vitro binding activity resepctively.

Razuprotafib is a potent protein tyrosine phosphatase β (HPTPβ) inhibitor..

Razuprotafib sodium is a potent protein tyrosine phosphatase β(HPTPβ) inhibitor..

RB-005 (RB-005) is a potent, selective inhibitor of sphingosine kinase SphK1 (SK1) with IC50 of 3.6 uM, displays 15-fold selectivity over SphK2..

RB-101 is an mixed enkephalinase inhibitor that inhibits Aminopeptidase N and Neutral Endopeptidase with IC50 of 11 nM and 2 nM, respectively.

RB394 is an orally bioavailable and dual modulator of soluble epoxide hydrolase (sEH) and PPARγ.

RBPI-4 is a selective small molecule inhibitor of poly(ADP-ribose) glycohydrolase (PARG) with IC50 of 3.0 uM, effectively inhibit PARG in cellular lysate..

RCGD423 is a gp130 modulator, which prevents articular cartilage degeneration and promotes repair.

RCM-1 (FOXM1 inhibitor RCM-1) is a nontoxic, small molecule that inhibits FOXM1 activity in vitro and in vivo, inhibits GFP-FOXM1 in U2OS cells with EC50 of 0.72 uM.

RD162 is a second-generation, orally available antiandrogen that binds to androgen receptor (AR) with IC50 of 30.9 nM.

REDX-05358 is a novel potent, highly selective, orally bioavailable pan RAF inhibitor with IC50 of 0.1, 0.68, 0.171, and 0.076 nM for ARAF, BRAF, BRAF (V600E), and CRAF, respectively.

Regorafenib hydrochloride (BAY73-4506) is a potent, orally active multikinase inhibitor that potently inhibits endothelial cell kinases in biochemical and cellular kinase phosphorylation assays with nanomolar range (IC50=3-200 nM).

Relacatib (SB-462795, GSK-462795) is a potent and orally bioavailable small molecule cathepsin inhibitor with Ki of 41, 68 and 53 pM for cathepsin K, L and V, respectively.

Remodelin Fluor is a small molecule analog of Remodelin, demonstrates in vivo activitiy against NAT10, significantly enhances the healthspan in a Lmna G609G HGPS mouse model..

Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.

Resminostat(RAS2410; 4SC-201) is a potent inhibitor of HDAC1/3/6(IC50=43-72 nM); less potent to HDAC8 with IC50 of 877 nM.

RET agonist BT13 is a novel small molecule GDNF receptor RET agonist, potently and selectively activates RET and its downstream intracellular signaling cascades in immortalized cells (EC50~20 uM).

Retapamulin is a topical antibiotic, which binds to both E. coli and S. aureus ribosomes with similar potencies with Kd of 3 nM.

RET-IN-23c is a potent and selective RET kinase inhibitor with IC50 of 61.2 nM, shows no significant inhibitory effect against VEGFR-2 and KDR.

Retinyl palmitate is an ester of Retinol and is the major form of vitamin A found in the epidermis. Retinyl palmitate has been widely used in pharmaceutical and cosmetic formulations.

RETRA hydrobromide is a small molecule mutant p53 reactivator that activates a set of p53-regulated genes and specifically suppresses mutant p53-bearing tumor cells in vitro and in mouse xenograft.

RETRA hydrochloride is a small molecule mutant p53 reactivator that activates a set of p53-regulated genes and specifically suppresses mutant p53-bearing tumor cells in vitro and in mouse xenograft.

RETRA is a small molecule mutant p53 reactivator that activates a set of p53-regulated genes and specifically suppresses mutant p53-bearing tumor cells in vitro and in mouse xenograft.

Retro 1 is the first small molecule inhibitor of plant toxin ricin, protects HeLa cells against Ricin, Stx1 and Stx2, selectively blocks retrograde toxin trafficking at the early endosome-TGN (trans-Golgi network) interface.

Retro 2 is the first small molecule inhibitor of plant toxin ricin, protects HeLa cells against Ricin, Stx1 and Stx2, selectively blocks retrograde toxin trafficking at the early endosome-TGN (trans-Golgi network) interface.

Rev1-IN-5 is a small molecule inhibitor of the C-terminal domain of Rev1 and the Rev1-interacting region protein-protein interaction (Rev1-CT/RIR PPI) with IC50 of 2.5 uM.

Revaprazan (SB-641257.

Revaprazan (SB-641257.

Revexepride (SSP 002358.

RG14620 is an epidermal growth factor receptor (EGFR) inhibitor, with IC50 values of 3 μM for HER 14 colony formation and 1 pM for HER 14 DNA synthesis.

RG7800 a small molecule SMN2 splicing modifier to enter human clinical trials to treat spinal muscular atrophy.

RG7834 (RO 7020322) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells.

RH01386 is a small molecule that protect pancreatic β cells against endoplasmic reticulum stress-induced cell death.

RH01687 is a small molecule that protect pancreatic β cells against endoplasmic reticulum stress-induced cell death.

Rheb inhibitor NR1 is a small molecule that binds Rheb in the switch II domain (IC50=2.1 uM, Kd=1.5 uM) and selectively blocks mTORC1 signaling, potently inhibits mTORC1 driven phosphorylation of S6K1 but does not inhibit phosphorylation of AKT or ERK.

Rho-kinase (ROCK) inhibitor

Rhosin (G04) is a potent, specific RhoA subfamily Rho GTPases inhibitor that specifically binds to RhoA to inhibit GEF reaction of RhoA with Kd of 0.4 uM, does not interact with Cdc42 or Rac1, nor the LARG.

Rhosin (G04) is a potent, specific RhoA subfamily Rho GTPases inhibitor that specifically binds to RhoA to inhibit GEF reaction of RhoA with Kd of 0.4 uM, does not interact with Cdc42 or Rac1, nor the LARG.

RHPS4 is a potent inhibitor of Telomerase at submicromolar.

Ribocil is a synthetic mimic of riboflavin 5’-monophosphate (FMN) that competes with the natural ligand to inhibit FMN riboswitch-mediated expression of ribB.

Riboflavine phosphate is a very effective NAD+-recycling agent.

Rifabutin (Mycobutin)

Rifaximin is an oral, semi-synthetic antibiotic derived from Rifamycin SV with antibacterial activity, interferes with transcription by binding to the β-subunit of bacterial RNA polymerase.

Rigosertib sodium (ON 01910.Na) is a potent, non-ATP-competitive PLK1 inhibitor (IC50=9-10 nM), selectively induces mitotic G2/M arrest and apoptosis in cancer cells.

Rimeporide (EMD87580) is a potent, selective sodium hydrogen exchanger NHE1 inhibitor, show promise as potential therapeutic agents for the treatment of heart failure..

Rimonabant Hcl(SR141716A) is a selective central cannabinoid (CB1) receptor inverse agonist with Ki of 1.8 nM.

Rimonabant(SR141716) is a selective central cannabinoid (CB1) receptor inverse agonist with Ki of 1.8 nM.

RIP1-IN-22 is a highly potent, orally available, and brain-penetrating RIP1 kinase inhibitor with pKi of 9.04.

RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) with an IC50 of 13 nM.

RIPGBM is a cell type-selective, small molecule inducer of apoptosis in GBM cancer stem cells (CSCs) with EC50 of 220 nM (GBM 1 cells).

RIPK2 inhibitor 1 is a novel potent, selective RIPK2 inhibitor with IC50 of 5-10 nM.

RIPK2 inhibitor OD36 is a potent, specific, ATP-competitive inhibitor of RIPK2 with IC50 of 5.3 nM, inhibits Tyr and Ser/Thr-directed activities of RIPK2.

Risdiplam (RG7916, RG-7916, RO7034067) is a highly potent, selective, orally active SMN2 splicing modifier for treatment of spinal muscular atrophy (SMA).

Rislenemdaz (MK 0657.

Rislenemdaz (MK 0657.

Risperidone(R 64 766) is a serotonin 5-HT2 receptor blocker(Ki= 0.16 nM) and a potent dopamine D2 receptor antagonist(Ki= 1.4 nM).

Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS,showed potent activity against COVID-19(SARS-COV-2) .

Rivipansel sodium (GMI-1070, PF-06460031) is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively.

RJR-2403 (Rivanicline, Metanicotine) is a potent, selective neuronal nicotinic ACh (nAChR) agonist with high affinity to rat brain cortex (Ki=26 nM), does not significantly activate muscle type nAChRs or muscarinic receptors.

RJR-2403 (Rivanicline, Metanicotine) is a potent, selective neuronal nicotinic ACh (nAChR) agonist with high affinity to rat brain cortex (Ki=26 nM), does not significantly activate muscle type nAChRs or muscarinic receptors.

RK-20449 (RK20449) is a potent, small molecule inhibitor of hematopoietic cell kinase (HCK) with IC50 of 0.43 nM.

RN-1734 is a transient receptor potential vanilloid 4 (TRPV4) antagonist, blocking calcium influx induced by the TRPV4 agonist 4α-phorbol 12,13-didecanoate with IC50 values of 2.3, 5.9, and 3.2 µM for human, mouse, and rat TRPV4, respectively.

RNase L-IN-2 is a small-molecule activator of RNase L with EC50 of 22 uM.

RNPA1000 is a potent, specific small molecule inhibitor of S. aureus RnpA RNA degradation activity (IC50=100-125 uM), limits S. aureus mRNA turnover and growth.

RNPA2000 is a small-molecule inhibitor of Staphylococcus aureus RnpA-mediated RNA turnover and tRNA processing (IC50=130 uM).

Ro 08-2750 (Ro 082750) is a potent, selective, non-peptide nerve growth factor (NGF) inhibitor that binds to NGF dimer with Kd of 1 uM.

RO 2443 is a potent, dual MDM2/MDMX antagonist that inhibits both MDM2 (IC50=33 nM) and MDMX (IC50=41 nM) binding to p53, but poor water solubility does not allow for a meaningful assessment of its cellular activity..

Ro 25-6981 is a potent and selective activity-dependent blocker of NMDA receptors containing the NR2B subunit.

Ro 25-6981 is a potent and selective activity-dependent blocker of NMDA receptors containing the NR2B subunit.

RO 27-3225 (RO27-3225, RO 273225) is a potent, selective melanocortin melanocortin receptor MC4R agonist with EC50 of 1 nM, >30-fold selectivity over MC3R.

Ro 28-1675 (Ro 0281675) is a potent allosteric GK activator with a SC1.5 value of 0.24± 0.0019 uM.

RO 28-2653 is a potent, selective and orally active matrix-metalloproteinases (MMPs) MMP2, MMP9 and MMP14 inhibitor with IC50 of 10, 12 and 10 nM, shows no activity against MMP3 and MMP1 (IC50>1 uM).

Ro 60-0175 is a potent, selective 5-HT2C receptor agonist with pKi of 9, 7.5, 5.4, 5.2 and 5.6 for human 5-HT2C, 2A, 1A, 6 and 7 receptors respectively.

Ro 60-0175 is a potent, selective 5-HT2C receptor agonist with pKi of 9, 7.5, 5.4, 5.2 and 5.6 for human 5-HT2C, 2A, 1A, 6 and 7 receptors respectively.

Ro 64-6198 is a nonpeptidic, selective, brain-penetrant agonist of nociceptin/orphanin FQ receptor (NOP receptor/ORL1) with pKi of 9.41.

RO495 is a very potent TYK2 inhibitor with a IC50 of 1.5nM on TYK2 as tested in cell-based pharmacological assays

RO-51 is a potent, selective and drug-like dual P2X3 and P2X2/3 antagonist with pIC50 of 8.7 and 8.3, respectively..

RO5126766(CH5126766) is a Raf/MEK dual kinase inhibitor.

RO5258638 is a small molecule inhibitor of CDK5-p25 protein-protein interaction with IC50 of 1.39 uM..

RO5258638 is a small molecule inhibitor of CDK5-p25 protein-protein interaction..

RO6889678 is a highly potent inhibitor of HBV capsid formation with attributes that are favorable for targeting the liver, whilst maintaining moderate peripheral exposure..

RO-7 is a novel small molecule, broad-spectrum inhibitor of influenza acidic polymerase (PA) protein endonuclease activity with EC50 of 3.2-16 nM in MDCK cells.

Robenacoxib is a nonsteroidal anti-inflammatory drug (NSAID) used in veterinary medicine for the relief of pain and inflammation in cats and dogs, a Cyclooxygenase(COX)-1 and COX-2 inhibitor..

Robotnikinin is asmall molecule that binds the extracellular Sonic Hedgehog (Shh) protein (Kd=3.1 uM) and blocks Shh-signaling in cell lines, human primary keratinocytes and synthetic model of human skin.

Rogaratinib (BAY 1163877) is a potent, selective, orally available pan-FGFR with IC50 of 15, <1, 19 and 33 nM for FGFR1, 2, 3 and 4, respectively.

Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively.

ROMK-IN-25 is a potent and selective ROMK channel (KCNJ1) inhibitor with IC50 of 72 nM.

ROMK-IN-32 is a potent, selective ROMK inhibitor with IC50 of 17 nM.

Roniciclib is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC50s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.

RORγt inverse agonist 22 is a potent, subtype selective RORγt inverse agonist with binding IC50 of 18 nM, displays >192-fold selectivity over RORα and RORβ.

RORγt inverse agonist 32 is a potent, orally bioavailable inverse agonist of RORγt with IC50 of 9 nM in SPA binding assays.

Roseoflavin is a chemical analog of FMN and riboflavin that has antimicrobial activity.

Rotigotine is dopamine D2 and D3 receptor agonist. Ki values are 13 and 0.71 nM for D2 and D3 respectively. Rotigotine also has significant affinity for 5-HT1A and adrenergic α2B receptors. Rotigotine exhibits antiparkinsonian acitivity.

Rottlerin (Mallotoxin.

Roxyl-WL is a highly potent and selective inhibitor of IDO1 with IC50 of 1 nM.

Roy-Bz is the first small-molecule PKCδ-selective activator with EC50 of 58.5 nM, binds to the PKCδ-C1-domain.

RP-1859 is a selective stimulator of S1P1 and S1P5 (S1P1 IC50 = 0.20 nM; S1P5 IC50 = 170 nM) used for the treatment of autoimmunity disease.

RP-1865 is a selective stimulator of S1P1 and S1P5 used for the treatment of autoimmunity disease.

RP-5063 (Brilaroxazine) is a multimodal dopamine and serotonin modulator with partial agonist activity at DA D2, D3, D4, 5-HT1A, and 5-HT2ARs, and antagonist activity at 5-HT2B, 5-HT6 and 5-HT7Rs.

RPL-554 (LS-193855, RPL554) is a potent, orally available, dual PDE3/PDE4 inhibitor with IC50 of 0.4 nM and 1479 nM, respectively.

Rpn11 inhibitor 35 is a potent, small molecule inhibitor of the proteasome subunit Rpn11 with IC50 of 400 nM,100-fold selectivity over Csn5 and 10-fold selectivity over AMSH.

RPR260243 was the first reported hERG channel activator.

RRD-251 hydrochloride is a small molecule disruptor of Rb/Raf-1 interaction, potently and selectively disrupts the Rb/Raf-1 (IC50=77 nM) but not Rb/E2F, Rb/prohibitin, Rb/cyclin E, and Rb/HDAC binding.